GlassScriptPhysician profile
James Blake
NPI 1720176381
$163,989.16
in general payments reported to CMS, 2019-2025
16 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,954 · 2020: $545 · 2021: $18.44 · 2022: $130K · 2023: $226 · 2024: $620 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $22K · Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $22,240.53 |
| Food and Beverage | $1,128.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $152,343.31 | 2022-2025 | Evis Exera III Colonovideoscope |
| Allergan, INC. | $9,316.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $993.44 | 2019-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $380.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.18 | 2019-2023 | Entyvio |
| Phathom Pharmaceuticals, INC. | $137.39 | 2024 | Voquezna |
| Regeneron Pharmaceuticals, INC. | $133.00 | 2023 | |
| Redhill Biopharma INC. | $128.19 | 2020 | |
| Biocryst US Sales Co., LLC | $127.49 | 2024 | Orladeyo |
| Glaukos Corporation | $67.29 | 2024 | Idose |
| Alfasigma USA, INC. | $49.03 | 2020 | |
| Gilead Sciences, INC. | $40.29 | 2019-2020 | |
| Qol Medical, LLC | $35.84 | 2019 | |
| Merck Sharp & Dohme LLC | $34.33 | 2019 | |
| Exact Sciences Corporation | $19.55 | 2024 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.